Search
Search Results
##search.searchResults.foundPlural##
-
GILTERITINIB (XOSPATA ®) IN TURKEY: EARLY ACCESS PROGRAM RESULTS Gilteritinib (XOSPATA ®) in Turkey
1416PDF: 901Suppl. Files: 454HTML: 235 -
MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS.
4655PDF: 1314HTML: 1913Untitled: 180Untitled: 175 -
Sorafenib induced Hand Foot Skin Rash in FLT3 ITD mutated Acute Myeloid leukemia- A case report and review of literature
1863PDF: 908HTML: 1767Sorafenib induced Hand Foot Skin Rash in FLT3 ITD mutated AML- IMAGES: 161 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2120PDF: 1691HTML: 377 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3581PDF: 885HTML: 6710 -
SUSTAINED REMISSION IN AN ELDERLY PATIENT WITH ACUTE MYELOID LEUKEMIA FOLLOWING GILTERITINIB TREATMENT AS THIRD-LINE SALVAGE THERAPY Long-lasting disease remission with third line therapy with gilteritinib
938PDF: 513HTML: 193 -
FLT3 Mutated Acute Myeloid Leukemia after CD19 CAR-T Cells
950PDF: 1205HTML: 110 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1719PDF: 1163HTML: 245 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2579PDF: 798HTML: 5212 -
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA OF THE ELDERLY: REVIEW OF THE LITERATURE AND PERSPECTIVES. Hematopoietic stem cell transplatation in the elderly fo Acute Myeloid Leukemia
1577PDF: 507HTML: 161 -
POST-TRANSPLANT RELAPSE IN ACUTE LEUKEMIA: COMPARATIVE VALUE OF MRD AND CHIMERISM.
704PDF: 388Suppl. Files: 120HTML: 112 -
RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES
3768PDF: 1656HTML: 11586Figures Haase: 198 -
OPTIMIZING TREATMENT, MINIMIZING RISK: THERAPEUTIC DRUG MONITORING IN HEMATOLOGICAL MALIGNANCIES
1033PDF: 1209Suppl. Files: 146HTML: 69 -
NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE NPM1 mutated, BCR-ABL1 positive myeloid neoplasms
1660PDF: 1173HTML: 201 -
TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
4313PDF: 1759HTML: 1106 -
THE IMPORTANCE OF TARGETED NEXT-GENERATION SEQUENCING USAGE IN CYTOGENETICALLY NORMAL MYELOID MALIGNANCIES Targeted next-generation sequencing usage in cytogenetically normal myeloid malignancies
1520PDF: 538HTML: 272 -
ARA-C, IDARUBICINE AND GENTUZUMAB OZOGAMICIN (AIM) AS SALVAGE TREATMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS
1675PDF: 806HTML: 936cover letter: 267 -
Complex and Multifaceted Therapy-Related Myeloid Neoplasm Following Laryngeal Cancer Treated with Cisplatin and Radiotherapy
1181PDF: 752HTML: 1348Figure 1: 186Figure 2: 188 -
THE ROLE OF SLC22A4 IN ACUTE MYELOID LEUKEMIA
477PDF: 243HTML: 78 -
A MULTICENTER EXPERIENCE FROM LEBANON IN CHILDHOOD AND ADOLESCENT ACUTE MYELOID LEUKEMIA:HIGH RATE OF EARLY DEATH IN CHILDHOOD ACUTE PROMYELOCYTIC LEUKEMIA.
2069PDF: 1114HTML: 7692cover letter paper final AML: 214 -
DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA
9050PDF: 6057HTML: 87956Fig.1b: 184Fig.1c: 188Fig.2a: 176Fig.2b: 175Fig.4: 188Fig.2c: 183Fig.3: 181Tab.1: 225Tab.2: 206Tab.3: 188Tab.4: 220Fig1a: 181 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1240PDF: 985HTML: 210 -
Massive pulmonary embolism at the onset of acute promyelocytic leukemia
3509PDF: 880HTML: 1653figure 1: 165Untitled: 188 -
Can Polycythemia Vera evolve from Acute Myeloid Leukemia? A Case Report Showing a Simultaneous Minor JAK2 V617F Mutated Clone, De novo polycythemia vera following AML remission
1658PDF: 746HTML: 246 -
NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL
2491PDF: 838HTML: 8820Efremov 1: 226Efremov 2: 189 -
RECENT ADVANCES IN THE 5Q- SYNDROME
2772PDF: 1809HTML: 3666Pellagatti Fig 1: 214Pellagatti Fig. 2: 210 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1374HTML: 394PDF: 819 -
The venetoclax/azacitidine combination targets the disease clone in Acute Myeloid Leukemia, being effective and safe in a patient with COVID VEN/AZA effectively targets AML clones
1233PDF: 756HTML: 313 -
EFFICACY OF VENETOCLAX COMBINED WITH AZACITIDINE IN ELDERLY PATIENTS WITH RELAPSED ACUTE MYELOID LEUKEMIA
1457PDF: 761Suppl. Files: 323Html: 135







